Skip to main content
. 2012 Jan 31;2012:612707. doi: 10.1155/2012/612707

Table 2.

Freedom from biochemical progression free-survival (BPFS), clinical progression-free (CPFS), cancer-specific (CSS), and overall survival (OS).

Projected survival Group 1 ADT (n = 86) Group 2 no ADT (n = 86) P value
5 years 10 years 5 years 10 years
BPFS 87.7% 76.3% 37.1% 30.6% <0.001
CPFS 96.9% 94.3% 73.7% 67.0% 0.003
CSS 100% 100% 100% 91.0% 0.9
OS 94.4% 83.8% 97.1% 76.4% 0.6